NEW YORK, Sept. 14, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Endo International plc (NASDAQ:ENDP) who purchased shares between November 30, 2012 and July 6, 2017. The action, which was filed in the USDC for the Eastern District of Pennsylvania, alleges that the Company violated federal securities laws.
The complaint alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose material information regarding the Company’s branded pharmaceutical Opana. In particular, the complaint alleges that the Company made materially false and/or misleading statements and/or failed to disclose that: (1) Reformulated Opana was not resistant to crushing; (2) Reformulated Opana was not abuse-deterrent and its use carried an inherent risk of abuse by grinding, snorting, or injecting; (3) Reformulated Opana was contributing to an opioid public health crisis; and (4) Endo would ultimately remove Reformulated Opana from the market.
Shareholders have until October 17, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sbm/endo-international-plc?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Joseph Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com


ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift
Italy Fines Apple €98.6 Million Over App Store Dominance
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
Uber and Baidu Partner to Test Robotaxis in the UK, Marking a New Milestone for Autonomous Ride-Hailing
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 



